Syed Husain Farhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syed Husain Farhan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hasan Mushahid
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Syeda Ayesha Shah
Dow University of Health Sciences
2 shared publications - Asad Ali Siddiqui
Dow University of Health Sciences, Department of Medicine, Karachi, Pakistan
1 shared publication - George V. Moukarbel
Division of Cardiovascular Medicine, University of Toledo Medical Center, Toledo, Ohio, USA
1 shared publication - Ishaque Hameed
Department of Medicine, MedStar Health, Baltimore, MD, USA
1 shared publication - Jeffrey E. Janis
Department of Plastic and Reconstructive Surgery, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
1 shared publication
Latest Publications
- Open Access
- 17 June 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (7) , 1777-1786
Does BMI Impact Outcomes in Patients Undergoing Open Abdominal Wall Reconstruction? A Systematic Review and Meta‐Analysis
Importance: Obesity is a significant factor that increases complication rates in patients undergoing abdominal wall reconstruction (AWR). This has led to caution about performing elective AWR in patients with higher body mass index (BMI). In light of this, our study aims to synthesize the current information on AWR outcomes in patients stratified according to the obesity classification, providing evidence‐based insights into the impact of BMI on AWR outcomes.Objective: To compare the clinical outcomes in patients of different BMI groups undergoing AWR.Data Sources: A systematic literature search of two databases (PubMed and Cochrane CENTRAL) from January 1st, 1966, until July 31, 2024, identified five relevant studies.Study Selection: Included in our analysis were original studies that assessed clinical outcomes in patients with a BMI < 35 kg/m2 compared to those with a BMI ≥ 35 kg/m2 undergoing elective AWR. Studies with a patient population of less than 18 years or oncologic patient population were excluded.Data Extraction and Synthesis: This systematic review and meta‐analysis are reported as per the PRISMA statement. As recommended by the Cochrane Collaboration, the Newcastle–Ottawa scale was used to evaluate methodological quality. The Mantel–Haenszel random‐effects method was used to calculate the pooled odds ratios (ORs) with their 95% confidence intervals (CIs).Main Outcome: The primary outcomes were hernia recurrence, readmission, reoperation, and surgical site infection (SSI).Results: Out of 4769 classifiable patients that underwent AWR, the majority were obese‐ CDC Class 1, 2 (2401; 50%) or morbidly obese‐Class 3 (1054; 22%). Patients with a BMI < 35 kg/m2 compared to a BMI ≥ 35 kg/m2 were associated with significantly decreased odds of readmission (OR 0.52, 95% CI 0.38–0.70, I2 = 0%, and p < 0.0001), reoperation (OR 0.72, 95% CI 0.55–0.93, I2 = 17%, and p = 0.01), and developing SSI (OR 0.62, 95% CI 0.48–0.81, I2 = 35%, and p = 0.0005), whereas hernia recurrence (OR 1.03, 95% CI 0.35–3.00, I2 = 88%, and p = 0.96) was statistically insignificant.Conclusion and Relevance: A patient's BMI should not be the sole determinant when planning elective AWR, as increasing BMI does not impact hernia recurrence rates. However, obese patients should be counseled on the higher risk of developing infections, requiring reoperation, and necessitating readmission due to their weight.
- 17 June 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (7) , 1777-1786
Open AccessDoes BMI Impact Outcomes in Patients Undergoing Open Abdominal Wall Reconstruction? A Systematic Review and Meta‐Analysis
Importance: Obesity is a significant factor that increases complication rates in patients undergoing abdominal wall reconstruction (AWR). This has led to caution about performing elective AWR in patients with higher body mass index (BMI). In light of this, our study aims to synthesize the current information on AWR outcomes in patients stratified according to the obesity classification, providing evidence‐based insights into the impact of BMI on AWR outcomes.Objective: To compare the clinical outcomes in patients of different BMI groups undergoing AWR.Data Sources: A systematic literature search of two databases (PubMed and Cochrane CENTRAL) from January 1st, 1966, until July 31, 2024, identified five relevant studies.Study Selection: Included in our analysis were original studies that assessed clinical outcomes in patients with a BMI < 35 kg/m2 compared to those with a BMI ≥ 35 kg/m2 undergoing elective AWR. Studies with a patient population of less than 18 years or oncologic patient population were excluded.Data Extraction and Synthesis: This systematic review and meta‐analysis are reported as per the PRISMA statement. As recommended by the Cochrane Collaboration, the Newcastle–Ottawa scale was used to evaluate methodological quality. The Mantel–Haenszel random‐effects method was used to calculate the pooled odds ratios (ORs) with their 95% confidence intervals (CIs).Main Outcome: The primary outcomes were hernia recurrence, readmission, reoperation, and surgical site infection (SSI).Results: Out of 4769 classifiable patients that underwent AWR, the majority were obese‐ CDC Class 1, 2 (2401; 50%) or morbidly obese‐Class 3 (1054; 22%). Patients with a BMI < 35 kg/m2 compared to a BMI ≥ 35 kg/m2 were associated with significantly decreased odds of readmission (OR 0.52, 95% CI 0.38–0.70, I2 = 0%, and p < 0.0001), reoperation (OR 0.72, 95% CI 0.55–0.93, I2 = 17%, and p = 0.01), and developing SSI (OR 0.62, 95% CI 0.48–0.81, I2 = 35%, and p = 0.0005), whereas hernia recurrence (OR 1.03, 95% CI 0.35–3.00, I2 = 88%, and p = 0.96) was statistically insignificant.Conclusion and Relevance: A patient's BMI should not be the sole determinant when planning elective AWR, as increasing BMI does not impact hernia recurrence rates. However, obese patients should be counseled on the higher risk of developing infections, requiring reoperation, and necessitating readmission due to their weight.
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
National Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
Open AccessNational Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.